Advances in targeted therapies for ovarian cancer
Prof Martin Gore - Royal Marsden Hospital and ICR, London, UK
7 Dec 2010
The influence of trabectedin on overall survival in ovarian cancer
Prof Nicoletta Colombo - European Institute of Milan, Italy
7 Dec 2010
The role of trabectedin in the treatment of ovarian cancer
Prof Bradley Monk - University of California at Irvine, USA
7 Dec 2010
CA-125 in the follow up of patients with ovarian cancer
Prof Christian Marth - Innsbruck Medical University, Austria
7 Dec 2010
The Cancer Genome Atlas
Dr Douglas Levine - Memorial Sloan-Kettering Cancer Center
7 Dec 2010
The development of ovarian cancer treatments
Dr Edward Trimble - National Cancer Institute, Maryland, USA
7 Dec 2010
The use of an intra-uterine device to treat early stage uterine cancer
Dr Lucas Minig - Hospital Universitario Madrid Sanchinarro, Spain
7 Dec 2010
The European Network of Young Gynae Oncologists
Dr. Murat Gultekin & Dr. Boris Vranes
7 Dec 2010
Key messages from IGCS 2010
Dr Richard Barakat - Memorial Sloan-Kettering Cancer Center, New York, USA
7 Dec 2010
GOG-218: Bevacizumab plus standard chemo for ovarian cancer
Prof Rob Coleman - University of Texas M.D. Anderson Cancer Center, Houston, USA
10 Nov 2010
Bevacizumab as part of standard first line treatment of ovarian cancer
Prof Jonathan Ledermann - University College London, UK
10 Nov 2010
The ICON7 trial
Prof Timothy Perren - Leeds Teaching Hospitals NHS Trust, UK
1 Nov 2010
